Evan Hall

Fantastic @StanfordDeptMed Grand Rounds now for the memorial @BGabster lecture @DianaCejasMD presents on writing and illness. & some basic neuroanatomy for us internists A special gathering for our community. Our gratitude to Dr. Gabster’s family. medicine.stanford.edu/news/current-n…

The Phase 2/3 Randomized trial of RP2+nivolumab for #uveal #melanoma is now OPEN at @StanfordCancer. This is for patients who have not had prior checkpoint inhibitors or liver-directed therapy. Prior tebentafusp is allowed. The phase 1 data were quite promising and we're excited to be able to offer this to our patients!

Representing ⁦@fredhutch⁩ ⁦@UWMedicine⁩ ⁦@uwsomwwami⁩ Kidney Cancer Multidisciplinary Team #IKCSNA2024 @KidneyCancer ⁦@spsutkaMD⁩

Nice to see this out there! Dr. Silk did a heroic job leading this trial of tvec and nivolumab in rare skin cancers. A collaboration that has spanned many institutions! ⁦@Perlmutter_CC⁩ ⁦@DanaFarber⁩ ⁦@theNCI⁩ ⁦@RutgersCancer⁩

Fantastic work @LisaTachiki @BhatiaS_MD @fredhutch et al. @FredHutchGO @HutchPresident @nicoleflemingmd @JessicaHawleyMD @RahulBanerjeeMD @EvanHallMD @btfoundation @binayshah @MonikaJoshimd @UWMedicine @AJPortuguese @HannahRAbrams @natashakwemd @valdesan @OncoAlert @sitcancer

New #JITC article: Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses bit.ly/4dIbUHP @BhatiaS_MD @PaulNghiem

Very thoughtfully designed study. Good rationale to reduce intensity of lymphodepletion. TIL can produce intracranial responses in some patients! Clearly, some pts have explosive disease kinetics and cannot wait (even w bridging) for this approach, but good to have pilot data 2/

@DrBetofMDPhD @StanfordCancer presents on TIL for patients with untreated brain metastases post PD-1 at #SMR24. Very important area to generate data. Time for TIL process, need for anesthesia/harvest, chemotherapy causing ⬇️plts, IL-2 etc complicate this scenario. 1/

Very proud to be part of multidisciplinary kidney cancer clinic ⁦@fredhutch⁩ providing 1 stop service for kidney cancer patients⁦@spsutkaMD⁩ ⁦@DanLinMD⁩ ⁦@schadegr⁩ ⁦@EvanHallMD⁩ ⁦@LisaTachiki⁩ ⁦@WinstonVuong⁩ ⁦@MartinMaMDPhD⁩

Find yourself doctors (and colleagues) that get excited about moving the field forward like @alexshoushtari and @DrBetofMDPhD Reunion of kindred spirits this morning at Living with Melanoma @AIMatMelanoma and @StanfordCancer

Are you interested in how to select side-effects for ePRO symptom monitoring ? We conducted a national modified Delphi to do just that for #immunotherapy side-effects in routine care and found limited coverage of clinically relevant side-effects by existing PROMs @JCOOP_ASCO

Excited to present @ASCO highlights in GU cancers in @ScrippsHealth in Seattle! So much great data to cover! @fredhutch @shilpaonc @Uromigos @urotoday @OncoAlert @valdesan @EvanHallMD @BhatiaS_MD @JessicaHawleyMD @RahulBanerjeeMD @montypal @neerajaiims @jrgralow @TiansterZhang

@HanZhuMD @nih_nhlbi @NIH @StanfordCVI @StanfordDeptMed @Joseph_C_Wu @SeanM_Wu @EldrinL Congrats Han!!

Proud to announce that we are now an R01 funded lab! We will be using single cell multi-omics in human samples & mouse models to test novel therapeutic pathways in cardiac sarcoidosis. #cardioimmunology @nih_nhlbi @NIH @StanfordCVI @StanfordDeptMed @Joseph_C_Wu @SeanM_Wu @EldrinL

That Seattle 5k was fantastic! 🤩 We had 122 people race for a cure with us! Thank you to each and every one of you! We are so appreciative of all of your support! 🥇 We were able to raise over $10,000! 👏 👏 👏 And we'd like to thank @fredhutch for sponsoring this event!

Heard this today at a funeral and it hit me like a ton of bricks

I don’t know who else needs to hear this, but I know I did

Check out our latest paper on the development of the new @EORTC_QLG advanced #melanoma module. Great to contribute 🇦🇺 perspectives from @MelanomaAus. @PeterMacCC patients will also be included in Phase 3. #melsm authors.elsevier.com/c/1jFvH3QE--Z9…

Great to see patient-reported outcomes (#PROs) 🔦at #ASCO24 across symptom science/ pall care + quality of care/ HSR tracks, incl as part of stepped models of care and in large real-world studies 👏👏. Here are my #ASCO24 PRO highlights:

As the sun sets on #asco24 I’d be remiss not to say that I’m worried about my colleagues I worry we are crushing one another with colossal expectations, with our emails & CVs You are more than your publications & presentations Please don’t tie your self-worth to brass rings

#irAE outcomes needs to be right next to Progression free survival and Disease free survival as a core outcome. Thank you @jillfeldman4 @thenasheffect @EladSharonMD @FunchainMD for amplifying this message. #ASCO24